Cancer drugs approved based on biomarkers and not tumor type: FDA approval of pembrolizumab for mismatch repair-deficient solid cancers Journal Article
| Authors: | Prasad, V.; Kaestner, V.; Mailankody, S. |
| Article Title: | Cancer drugs approved based on biomarkers and not tumor type: FDA approval of pembrolizumab for mismatch repair-deficient solid cancers |
| Keywords: | braf; vemurafenib |
| Journal Title: | JAMA Oncology |
| Volume: | 4 |
| Issue: | 2 |
| ISSN: | 2374-2437 |
| Publisher: | American Medical Association |
| Date Published: | 2018-02-01 |
| Start Page: | 157 |
| End Page: | 158 |
| Language: | English |
| ACCESSION: | WOS:000424778600005 |
| DOI: | 10.1001/jamaoncol.2017.4182 |
| PROVIDER: | wos |
| PUBMED: | 29285544 |
| Notes: | Editorial Material -- Source: Wos |
